1432/1/12/22 Advanz Pharma Corp v Competition and Markets Authority

The President made an order on 18 February 2022 granting an extension of time for Advanz to file a notice of appeal in respect of the CMA's decision of 3 February 2022 regarding the supply of Prochlorperazine tablets in the UK (Case 50511-2). 

By an Order of the President dated 26 April 2022, the time for the CMA to file a single consolidated Defence was extended to 20 June 2022.

A summary of appeal was published on 16 May 2022.

A case management conference took place on 9 September 2022. On 18 October 2022, pursuant to the Order of Mr Justice Edwin Johnson, a claim issued by the CMA seeking competition disqualification orders to be made against each of the Defendants pursuant to s9A of the Company Directors Disqualification Act 1986, was transferred to the Tribunal ("the Transferred Proceeding"). A further case management conference was held on 14 November 2022, following which it was ordered that the Transferred Proceeding be heard together with the appeals. 

A pre-trial review was held on 18 May 2023. The appeals were heard between 5 – 27 June 2023 and 26 July – 4 August 2023.

On 23 May 2024, the Tribunal unanimously allowed the appeals and set aside the CMA's decision ([2024] CAT 36).